Understanding Immune Response to Photodynamic Therapy for Basal Cell Carcinoma
This study aims to understand how your body's immune system responds to basal cell carcinoma (BCC) when treated with Photodynamic Therapy (PDT). PDT uses a special drug called ALA applied to the skin and then activated by blue light to kill cancer cells. Researchers want to see if PDT changes certain immune cells and molecules in BCC tumors, which could help develop better treatments in the future. You might be able to join if you are an adult (over 18) with at least one BCC tumor scheduled for surgical removal at Cleveland Clinic. The study will look for changes in immune cells and molecules in your tumor within 1-14 days after PDT. The study's current status is unclear, and it plans to enroll 18 participants.
- Study design
- This is an interventional study with 18 planned participants. It's an internally controlled trial where one tumor will receive PDT and another will be an untreated control.
- What's involved
- You would have ALA applied to one BCC lesion, followed by PDT with blue light for 30 minutes. Tissue samples will be taken at a second visit within 1-14 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your immune response will be measured within 1-14 days after PDT treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Edward V Maytin, MD, PhD · PRINCIPAL_INVESTIGATOR · Cleveland Clinic, Case Comprehensive Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Time to maximum expression of immune checkpoint moleculesat visit 2 (1-14 days)
Time (days) to maximum expression of immune checkpoint molecules in BCC tumors and peri-tumoral stroma after PDT, as compared to untreated tumors. Data from frozen BCC specimens post-PDT by immunostaining the tumor specimens with antibodies against PD-L1, PD-1, CTLA-4 as well as the newer IC molecules TIGIT, TIM-3, and LAG-3
- Altered expression of immune checkpoint moleculesat visit 2 (1-14 days)
Altered expression of immune checkpoint molecules in BCC tumor specimens after PDT. Assessed by comparing IC molecule expression in PDT treated and untreated tumors with immunostaining in the tumor specimens with antibodies against PD-L1, PD-1, CTLA-4 as well as the newer IC molecules TIGIT, TIM-3, and LAG-3. (quantifying with immunofluorescence microscope)
- Altered recruitment of different immune cell subtypes in BCC tumor specimensat visit 2 (1-14 days)
Determine the ratio of cytotoxic T cells to regulatory T cells in BCC tumors and peri-tumoral stroma after PDT, as compared to untreated tumors. Measured with specific antibodies against the following markers, to determine the qualitative time course of infiltration by each immune cell populations: Neutrophils (Gr1+ or MPO+); Macrophages(F4/80+); MDSCs (CD33, S100A9); cytotoxicT-cells(CD8+); regulatory T-cells(CD4+,FoxP3+,CD25+, CD127-); NK natural killer cells(CD56+CD16+).